U.S. Colorectal Cancer Markets - Patient Outlook

Frost & Sullivan
December 15, 2006
36 Pages - SKU: MC1461624
License type:
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a  |  more...
$3,995.00
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity Summary GBI Research, the leading  |  more...
$3,500.00
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors  |  more...
$3,995.00
Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is evaluated  |  more...
$5,175.00
2012 European Tumor Marker Testing Market:France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies
4/24/2012 | published by: Venture Planning Group
This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and evaluates major business opportunities emerging in the cancer diagnostics  |  more...
$18,500.00
2012 World Cancer Diagnostic Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country
4/17/2012 | published by: Venture Planning Group
This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, estimates of the number of laboratories performing cancer tests, as  |  more...
$950.00
Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar  |  more...
$5,175.00
Triple Analysis: Leukemia, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is evaluated  |  more...
$5,175.00
Triple Analysis: Lymphoma, Pancreatic Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria  |  more...
$5,175.00
Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized  |  more...
$5,175.00